Vanda Pharmaceuticals (NASDAQ: VNDA) is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs.
The company has assembled an experienced team along with a portfolio of clinical and commercial stage programs with the goal of bringing important new treatment options to patients.
Date Amount / Round Valuation Lead Investor Investors Oct, 2014 $54M / Post Ipo Equity — — 0 Business Development & Licensing
Date News May 27, 2016 Sarasota Herlad - US stocks edge higher, led by consumer companies and banks May 25, 2016 Med City News - Company offers concierge services for participants in clinical trials Jan 22, 2016 PRNewswire All - Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 10, 2016 Conference Call and Webcast to Follow Dec 23, 2015 PRNewswire All - European Medicines Agency Accepts Fanaptum® (iloperidone) Marketing Authorization Application for the Treatment of Schizophrenia in Adults Nov 30, 2015 Business Wire - Research and Markets: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review Report H2 2015 Nov 24, 2015 PRNewswire All - HemoShear Therapeutics Names H. Thomas Watkins to Board of Directors Nov 3, 2015 PRNewswire All - Vanda Pharmaceuticals Reports Third Quarter 2015 Financial Results Jul 24, 2015 PRNewswire UK All - Ophthalmic Drugs Market Forecast 2015-2025: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs Headquarters
2200 Pennsylvania Ave NW
Washington, DC 20037
Vice President, Corporate Development @ Naurex